


**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

**Complete if Known**

<b>Application Number</b>	10/813,954
<b>Filing Date</b>	03-31-2004
<b>First Named Inventor</b>	JAEHNE et al.
<b>Group Art Unit</b>	1614
<b>Examiner Name</b>	BERCH Mark L.
<b>Attorney Docket Number</b>	DEAV2003/0028 - US - NP

**(use as many sheets as necessary)**

Sheet	1	of	5	Attorney Docket Number	DEAV2003/0028 - US - NP
-------	---	----	---	------------------------	-------------------------



## U.S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials <sup>2</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	To
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
MB		EP	0 656 354		BARTH, et al.	06-04-1997		
		EP	0462884		VINCENT, et. al.	06-16-1993		
		WO	02/44150		BOKOTEY, et al.	06-06-2002		
		WO	00/34331		DONG, et. al.	06-15-2000		
		WO	00/40569		HODSON, et. al.	07-13-2000		
		WO	00/64876		JAYYOSI, et. al.	11-02-2000		
		WO	00/64888		JAYYOSI, et. al.	11-02-2000		
		WO	00/71549		BROUGH et al	11-30-2000		
		WO	00/78312		SAHOO, et. al.	12-28-2000		
MB		WO	01/04156		LARSEN, et al.	01-18-2001		

05/12/2006

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.





+

**Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.**

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>				<b>Complete if Known</b>	
				Application Number	10/813,954
				Filing Date	03-31-2004
				First Named Inventor	JAEHNE et al.
				Group Art Unit	1614
				Examiner Name	BERCH Mark L.
				Attorney Docket Number	DEAV2003/0028 - US - NP
Sheet	3	of	5		

[illegible][illegible]

Examiner Signature	/Mark L. Berch/	Date Considered	05/12/2006
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO:** Assistant Commissioner for Patents, Washington, DC 20231.

Please type a plus sign (+) inside this box → ☐

PTO/SB/088 (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO			<b>Complete if Known</b>		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)			Application Number	10/813,954	
			Filing Date	03-31-2004	
			First Named Inventor	JAEHNE et al.	
			Group Art Unit	1614	
			Examiner Name	BERCH Mark L.	
Sheet	4	of	5	Attorney Docket Number	DEAV2003/0028 - US - NP

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
MB		ASAKAWA A. et al., Cocaine-Amphetamine-Regulated Transcript Influences Energy Metabolism, Anxiety and Gastric Emptying in Mice, Hormone and Metabolic Research, (2001) Vol. 33, No. 9, pp. 554 - 558	
		BARF Tjeerd et al., Arylsulfonamidothiazoles as a New Class of Potential Antidiabetic Drugs. Discovery of Potent and Selective Inhibitors of the 11 Beta-Hydroxysteroid Dehydrogenase Type 1, American Chemical Society, (2002), Vol. 45, No. 18, pp. 3813 - 3815	
		ISHIHARA Kazuaki et al., 3,4,5-Trifluorobenzeneboronic Acid as an Extremely Active Amidation Catalyst, J. Org. Chem., (1996), Vol. 61, pp. 4196 - 4197	
		KLAUSNER Yakir S. et al., Coupling Reagents in Peptide Synthesis	
		KUNISHIMA Munetaka et al., 4-(4,6-Dimethoxy-1,3,5-triazin-2-yl)-4-methyl-morpholinium Chloride: An Efficient Condensing Agent Leading to the Formation of Amides and Esters, Tetrahedron, (1999), Vol. 55, pp. 13159 - 13170	
		LAROCK, R.C., Interconversion of Nitriles, Carboxylic Acids and Derivatives, Comprehensive Organic Transformations: A Guide to Functional Group Preparations, VCH Publishers, New York, Weinheim; 1999; pp.1929-1930.	
		LEE Daniel W. et al., Leptin Agonists as a Potential Approach to the Treatment of Obesity, Drugs of the Future, (2001), Vol. 26, No. 9, pp. 873 - 881	
		OKADA H. et al., Synthesis and Antitumor Activities of Prodrugs of Benzoylphenylureas, Chem. Pharm. Bull., (1994), Vol. 42, No. 1, pp. 57 - 61	
		SALVADOR Javier et al., Perspectives In The Therapeutic Use Of Leptin, Expert Opinion Pharmacotherapy, (2001), Vol. 2, No. 10, pp. 1615 - 1622	
MB		SPEICHER A. et al., O-(1-Benzotriazolyl)-N,N,N,N-tetramethyluroniumhexafluorophosphat (HBTU) und O-(7-Aza-1-benzotriazolyl)-N,N,N,N-tetramethyluroniumhexafluorophosphat (HATU) - zwei moderne Kupplungsreagenzien zur Peptidsynthese, J. prakt. Chem., (1998), Vol. 340, pp. 581 - 583	

Examiner Signature	/Mark L. Berch/	Date Considered	05/12/2006
--------------------	-----------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



+

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(use as many sheets as necessary)</i>			<b>Complete if Known</b> <table border="1"> <tr> <td>Application Number</td> <td>10/813,954</td> </tr> <tr> <td>Filing Date</td> <td>03-31-2004</td> </tr> <tr> <td>First Named Inventor</td> <td>JAEHNE et al.</td> </tr> <tr> <td>Group Art Unit</td> <td>1614</td> </tr> <tr> <td>Examiner Name</td> <td>BERCH Mark L.</td> </tr> <tr> <td>Attorney Docket Number</td> <td>DEAV2003/0028 - US - NP</td> </tr> </table>		Application Number	10/813,954	Filing Date	03-31-2004	First Named Inventor	JAEHNE et al.	Group Art Unit	1614	Examiner Name	BERCH Mark L.	Attorney Docket Number	DEAV2003/0028 - US - NP
Application Number	10/813,954															
Filing Date	03-31-2004															
First Named Inventor	JAEHNE et al.															
Group Art Unit	1614															
Examiner Name	BERCH Mark L.															
Attorney Docket Number	DEAV2003/0028 - US - NP															
Sheet	5	of	5													

[illegible]

Examiner Signature	/Mark L. Berch/	Date Considered	05/12/2006
-----------------------	-----------------	--------------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**